Wedbush Maintains an 'Outperform' on Nektar Therapeutics (NKTR), Recent Marketing Trip Focused on Upcoming Ovarian Cancer Data
Tweet Send to a Friend
Wedbush maintains an Outperform on Nektar Therapeutics (Nasdaq: NKTR), raises price target from $11 to $12.
Wedbush analyst says, "Chief ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "Chief ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
